Digest Network Come funziona
Network
/
Società
Ec
Non verificato

Eccogene

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

5 comunicati stampa

Guarda tutti i comunicati
28/09/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
Fonte
Eccogene
Emittente
Business Wire
1.00
0
01/06/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
Industria
Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026
Fonte
Eccogene
Emittente
Business Wire
1.00
0
16/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity
Fonte
Eccogene
Emittente
Business Wire
1.00
0
10/02/2026
Biotecnologia
Farmaceutica
Sanità
Salute
Fitness
Medicina - Varie
Industria
Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
Fonte
Eccogene
Emittente
Business Wire
1.00
0
16/12/2025
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH
Fonte
Eccogene
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0